Topoisomerase IIα as a marker predicting the efficacy of anthracyclines in breast cancer: Are we at the end of the beginning?

Clinical Breast Cancer

Volumn 4, Issue 3, 2003, Pages 179-186

  Di Leo, Angelo ^a   Isola, Jorma ^b  

^a JULES BORDET INSTITUTE   (Belgium)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

c erbB 2; Estrogen receptor; Gene amplification; HER2

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; TRASTUZUMAB; TUMOR MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL RESEARCH; CLINICAL STUDY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG SENSITIVITY; GENE AMPLIFICATION; HUMAN; IN VITRO STUDY; ONCOGENE NEU; PREDICTION; PROTEIN EXPRESSION; REVIEW;

EID: 0141614011     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1526-8209(11)70623-1     Document Type: Review

References (53)

1. Polychemotherapy for Early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 352:930-942.
2. Hutchins L, Green S, Ravdin P, et al. CMF versus CAF with and without tamoxifen in high-risk node negative breast cancer patients and a natural history follow-up study in low-risk node negative patients: first results of Intergroup trial INT 0102. Proc Am Soc Clin Oncol 1998; 17:1a (Abstract #2).
3. Mouridsen HT, Andersen J, Anderson M, et al. Adjuvant anthracycline in breast cancer. Improved outcome in premenopausal patients following substitution of methotrexate in the CMF combination with epirubicin. Proc Am Soc Clin Oncol 1999; 18:68a (Abstract #254).
4. Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998; 16:2651-2658.
5. Piccart MJ, Di Leo A, Beauduin M, et al. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 2001; 19:3103-3110.
6. Zambetti M, Moliterni A, Materazzo C, et al. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol 2001; 19:37-43.
7. Bonneterre JM, Roche H, Kerbrat P, et al. Long-term follow-up in free of disease patients after receiving 6 FEC 50 vs 6 FEC 100 (FASG-05 trial) as adjuvant chemotherapy for node-positive breast cancer. Proc Am Soc Clin Oncol 2002; 21:39a (Abstract #154).
8. Perez EA, Hortobagyi GN. Ongoing and planned adjuvant trials with trastuzumab. Semin Oncol 2000; 27:26-32.
9. Wang JC. DNA topoisomerases. Annu Rev Biochem; 1996; 65:635-692.
10. Kingma PS, Osheroff N. The response of eukaryotic topoisomerases to DNA damage. Biochim Biophys Acta 1998; 1400:223-232.
11. Meyer KN, Kjeldsen E, Straub T, et al. Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities. J Cell Biol 1997; 136:775-788.
12. Froelich-Ammon SJ, Osheroff N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J Biol Chem 1995; 270:21429-21432.
13. Burden DA, Osheroff N. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim Biophys Acta 1998; 1400:139-154.
14. Isaacs RJ, Davies SL, Wells NJ, et al. Topoisomerases II alpha and beta as therapy targets in breast cancer. Anticancer Drugs 1995; 6:195-211.
15. Withoff S, Keith WN, Knol AJ, et al. Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel. Br J Cancer 1996; 74:502-507.
16. Withoff S, de Vries EG, Keith WN, et al. Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4. Br J Cancer 1996; 74:1869-1876.
17. Gudkov AV, Zelnick CR, Kazarov AR, et al. Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc Natl Acad Sci U S A 1993; 90:3231-3235.
18. Vassetzky YS, Alghisi GC, Roberts E, et al. Ectopic expression of inactive forms of yeast DNA topoisomerase II confers resistance to the anti-tumour drug, etoposide. Br J Cancer 1996; 73:1201-1209.
19. Asano, T, An T, Mayes J, et al. Transfection of human topoisomerase II alpha into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene. Biochem J 1996; 319(Pt 1)307-313.
20. Asano T, Zwelling LA, An T, et al. Effect of transfection of a Drosophila topoisomerase II gene into a human brain tumour cell line intrinsically resistant to etoposide. Br J Cancer 1996; 73:1373-1380.
21. Mo YY, Ameiss KA, Beck WT. Overexpression of human DNA topoisomerase II alpha by fusion to enhanced green fluorescent protein. Biotechniques 1998; 25:1052-1057.
22. Jarvinen TA, Kononen J, Pelto-Huikko M, et al. Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am J Pathol 1996; 148:2073-2082.
23. Smith K, Houlbrook S, Greenall M, et al. Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene 1993; 8:933-938.
24. Keith WN, Douglas F, Wishart GC, et al. Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20. Eur J Cancer 1993; 29A:1469-1475.
25. Murphy DS, McHardy P, Coutts J, et al. Interphase cytogenetic analysis of erbB2 and topoII alpha co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ. Int J Cancer 1995; 64:18-26.
26. Hoare SF, Freeman CA, Coutts JC, et al. Identification of genetic changes associated with drug resistance by reverse in situ hybridization. Br J Cancer 1997; 75:275-282.
27. Jarvinen TA, Tanner M, Barlund M, et al. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 1999; 26:142-150.
28. Jarvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000; 156:839-847.
29. Kauraniemi P, Barlund M, Monni O, et al. New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. Cancer Res 2001; 61:8235-8240.
30. Jin Y, Hoglund M, Jin C, et al. FISH characterization of head and neck carcinomas reveals that amplification of band 11q13 is associated with deletion of distal 11q. Genes Chromosomes Cancer 1998; 22:312-320.
31. Tanner MM, Karhu RA, Nupponen NN, et al. Genetic aberrations in hypodiploid breast cancer: frequent loss of chromosome 4 and amplification of cyclin D1 oncogene. Am J Pathol 1998; 153:191-199.
32. Prost S. Mechanisms of resistance to topoisomerases poisons. Gen Pharmacol 1995; 26:1673-1684.
33. Nitiss JL, Beck WT. Antitopoisomerase drug action and resistance. Eur J Cancer 1996; 32A:958-966.
34. Pegram MD, Finn RS, Arzoo K, et al. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 1997; 15:537-547.
35. Gancberg D, Di Leo A, Cardoso F, et al, Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002; 13:1036-1043.
36. Simon R, Nocito A, Hubscher T, et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001; 93:1141-1146.
37. Tanner M, Jarvinen P, Isola J. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res 2001; 61:5345-5348.
38. Durbecq V, Di Leo A, Cardoso F, et al. Comparison of topoisomerase-IIalpha gene status between primary breast cancer and corresponding distant metastatic sites. Breast Cancer Res Treat 2003; 77:199-204.
39. Durbecq V, Desmedt C, Di Leo A, et al. Correlation between topoisomerase IIα gene amplification and protein expression in HER-2 amplified breast cancer patients. Proc Am Assoc Cancer Research 2003; In press.
40. Sotiriou C, Neo SY, McShane L, et al. Breast cancer classification and prognosis based on gene expression profiles from a population based study. Proc Natl Acad Sci U S A 2003. In press.
41. Di Leo A, Gancberg D, Larsimont D, et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002; 8:1107-1116.
42. Coon JS, Marcus E, Gupta-Burt S, et al. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 2002; 8:1061-1067.
43. Park K, Kim J, Lim S, et al. Interaction between HER-2/neu and topoisomerase IIα amplification in preoperative doxorubicin-based chemotherapy for locally advanced breast cancer: integration of novel chromogenic in situ hybridization and tissue microarray technology. Eur J Cancer 2002; 38(suppl 3):S52 (Abstract #51).
44. Isola JJ. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol 1993; 170:31-35.
45. Cardoso F, Durbecq V, Bernard-Marty C, et al. Topoisomerase IIα amplification as potential predictive marker of complete response to anthracycline-based chemotherapy in locally advanced/metastatic breast cancer. Breast Cancer Res Treat 2002; 76(suppl 1):S64 (Abstract #218).
46. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001; 19:2334-2356.
47. Di Leo A, Larsimont D, Gancberg D, et al. HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol 2001; 12:1081-1089.
48. Wilt M, Millon R, Velten M, et al. Comparative value of SBR grade, hormonal receptors, Ki 67; HER-2 and topoisomerase IIα status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Proc Am Assoc Cancer Research 2002; 21:32a (Abstract #123).
49. Burcombe RJ, Makris A, Wilson G, et al. Evaluation of topoisomerase IIα as a predictor of clinical and pathological response to neoadjuvant chemotherapy in operable breast cancer. Proc Am Soc Clin Oncol 2002; 21:447a (Abstract #1785).
50. Jarvinen TAH, Holli K, Kuukasjarvi T, et al. Predictive value of topoisomerase IIα and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 1998; 77:2267-2273.
51. Earl H, Poole C, Dunn J, et al. NEAT: National Epirubicin Adjuvant Trial, a multicenter phase III randomized trial of epirubicin × 4 and classical DMF × 4 vs CMF × 6. Proc Am Soc Clin Oncol 2002; 21:60b (Abstract #2050).
52. Lowe SW, Bodis S, McClatchey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266:807-810.
53. Aas T, Borresen AL, Geisler S, et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996; 2:811-814.